Discovery of 4-amino-l-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4- carboxamides as selective, orally active inhibitors of protein kinase B (Akt)

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2239-2249

  McHardy, Tatiana ^a   Caldwell, John J ^a   Cheung, Kwai Ming ^a   Hunter, Lisa J ^a   Taylor, Kevin ^a   Rowlands, Martin ^a   Ruddle, Ruth ^a   Henley, Alan ^a   De Brandon, Alexis Haven ^a   Valenti, Melanie ^a   Davies, Thomas G ^b   Fazal, Lynsey ^b   Seavers, Lisa ^b   Raynaud, Florence I ^a   Eccles, Suzanne A ^a   Wynne Aherne, G ^a   Garrett, Michelle D ^a   Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 TERT BUTYLBENZYL) 1 (7H PYRROLO [2,3 D] PYRIMIDIN 4 YL) PIPERIDIN 4 AMINE; 4 AMINO 1 (7H PYRROLO [2,3 D] PYRIMIDIN 4 YL) PIPERIDINE 4 CARBOXAMIDE; 4 AMINO 4 BENZYLPIPERIDINE DERIVATIVE; 4 AMINO N (4 CHLOROBENZYL) 1 (7H PYRROLO [2,3 D] PYRIMIDIN 4 YL) PIPERIDINE 4 CARBOXAMIDE; 4 BENZYL 1 [7H PYRROLO (2,3 D) PYRIMIDIN 4 YL] PIPERIDIN 4 AMINE; AMIDE; AMINE; ANTINEOPLASTIC AGENT; PIPERIDINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LIPOPHILICITY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HALF-LIFE; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949419584     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901788j     Document Type: Article

References (51)

1. Sale, E. M.; Sale, G. J. Protein kinase B: signalling roles and therapeutic target. Cell. Mol. Life Sci. 2008, 65, 113-127.
2. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J. F. M. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic application. Curr. Cancer Drug Targets 2008, 8, 187-198.
3. Milburn, C. C.; Deak, M.; Kelly, S. M.; Price, N. C.; Alessi, D. R.; Van Aalten, D. M. F. Binding of phoisphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J. 2003, 375, 531-538.
4. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101.
5. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; De Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8, 393-412.
6. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT kinases in cancer: implications for cancer therapeutics. Adv. Cancer Res. 2005, 94, 29-86.
7. Lindsley, C. W.; Barnett, S. F.; Yaroschak, M.; Bilodeau, M. T. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr. Top. Med. Chem. 2007, 7, 1349-1363.
8. Lindsley, C. W.; Barnett, S. F.; Layton, M. E.; Bilodeau, M. T. The PI3/Akt Pathway: Recent progress in the development of ATPcompetitive and allosteric Akt kinase inhibitors. Curr. Cancer Drug Targets 2008, 8, 7-18.
9. Li, Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin. Ther. Patents 2007, 17, 1077-1130.
10. Collins, I. Targeted small molecule inhibitors of protein kinase B as anticancer agents. Anti-Cancer Agents Med. Chem. 2009, 9, 32-50.
11. (a) Luo, Y.; Shoemaker, A. R.; Liu, X.; Woods, K. W.; Thomas, S. A.; de Jong, R.; Han, E. K.; Li, T.; Stoll, V. S.; Powlas, J. A.; Oleksijew, A.; Mitten, M. J.; Shi, Y.; Guan, R.; McGonigal, T. P.; Klinghofer, V.; Johnson, E. F.; Leverson, J. D.; Bouska, J. J.; Mamo, M.; Smith, R. A.; Gramling-Evans, E. E.; Zinker, B. A.; Mika, A. K.; Nguyen, P. T.; Oltersdorf, T.; Rosenberg, S. H.; Li, Q.; Giranda, V. L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 2005, 4, 977-986.
12. (b) Woods, K. W.; Fischer, J. P.; Claiborne, A.; Li, T.; Thomas, S. A.; Zhu, G.; Diebold, R. B.; Liu, X.; Shi, Y.; Klinghofer, V; Han, E. K.; Guan, R.; Magnone, S. R.; Johnson, E. F.; Bouska, J. J.; Olson, A. M.; de Jong, R.; Oltersdorf, T.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L.; Li, Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg. Med. Chem. 2006, 14, 6832-6846.
13. (c) Li, Q; Woods, K. W.; Thomas, S.; Zhu, G. D.; Packard, G.; Fisher, J.; Li, T.; Gong, J.; Dinges, J.; Song, X.; Abrams, J.; Luo, Y.; Johnson, E. F.; Shi, Y.; Liu, X.; Klinghofer, V; Des Jong, R.; Oltersdorf, T.; Stoll, V. S.; Jakob, C. G.; Rosenberg, S. H.; Giranda, V. L. Synthesis and structure-activity relationship of 3,4′-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/ Akt) for the treatment of cancer. Bioorg. Med. Chem. Lett. 2006, 16, 2000-2007.
14. (d) Zhu, G. D.; Gong, J.; Claiborne, A.; Woods, K. W.; Gandhi, V. B.; Thomas, S.; Luo, Y.; Liu, X.; Shi, Y.; Guan, R.; Magnone, S. R.; Klinghofer, V; Johnson, E. F.; Bouska, J.; Shoemaker, A.; Oleksijew, A.; Stoll, V. S.; De Jong, R.; Oltersdorf, T.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorg. Med. Chem. Lett. 2006, 16, 3150-3155.
15. (e) Zhu, G. D.; Gandhi,V. B.; Gong, J.; Luo, Y.; Liu, X.; Shi, Y.; Guan, R.; Magnone, S. R.; Klinghofer, V; Johnson, E. F.; Bouska, J.; Shoemaker, A.; Oleksijew, A.; Jarvis, K.; Park, C.; Jong, R. D.; Oltersdorf, T.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg. Med. Chem. Lett. 2006, 16, 3424-3429.
16. (f) Thomas, S. A.; Li, T.; Woods, K. W.; Song, X.; Packard, G.; Fischer, J. P.; Diebold, R. B.; Liu, X.; Shi, Y; Klinghofer, V; Johnson, E. F.; Bouska, J. J.; Olson, A.; Guan, R.; Magnone, S. R.; Marsh, K.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L.; Li, Q. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Aktl kinase. Bioorg. Med. Chem. Lett. 2006, 16, 3740-13704
17. (g) Zhu, G. D.; Gong, J.; Gandhi, V. B.; Woods, K.; Luo, Y.; Liu, X.; Guan, R.; Klinghofer, V; Johnson, E. F.; Stoll, V. S.; Mamo, M.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Design and synthesis of pyridine- pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorg. Med. Chem. 2007, 15, 2441-2452.
18. (h) Zhu, G. D.; Gandhi, V. B.; Gong, J.; Thomas, S.; Woods, K. W.; Song, X.; Li, T.; Diebold, R. B.; Luo, Y; Liu. X.; Guan, R.; Klinghofer, V.; Johnson, E. F.; Bouska, J.; Olson, A.; Marsh, K. C.; Stoll, V. S.; Mamo, M.; Polakowski, J.; Campbell, T. J.; Martin, R. L.; Gintant, G. A.; Penning, T. D.; Li, Q.; Rosenberg, S. H.; Giranda, V. L. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J. Med. Chem. 2007, 50, 2990-3003.
19. (a) Breitenlechner, C. B.; Wegge, T.; Berillon, L.; Graul, K.; Marzenell, K.; Friebe, W. G.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R. A.; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 2004, 47, 1375-1390.
20. (b) Breitenlechner, C. B.; Friebe, W. G.; Brunet, E.; Werner, G.; Graul, K.; Thomas, U.; Kunkele, K. P.; Schafer, W.; Gassel, M.; Bossemeyer, D.; Huber, R.; Engh, R. A.; Masjost, B. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 2005, 48, 163-170.
21. Ko, J. H.; Yeon, S. W.; Ryu, J. S.; Kim, T. Y.; Song, E. H.; You, H. J.; Park, R. E.; Ryu, C. K. Synthesis and biological evaluation of 5-arylamino-6-chloro-l/H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg. Med. Chem. Lett. 2006, 16, 6001-6005.
22. (a) Collins, I.; Caldwell, J.; Fonseca, T.; Donald, A.; Bavetsias, V.; Rowlands, M. G.; Hunter, L.-J. K.; Garrett, M. D.; Davies, T. G.; Berdini, V.; Woodhead, S.; Davis, D.; Seavers, L. C. A.; Wyatt, P. G.; McDonald, E. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg. Med. Chem. 2006, 14, 1255-1273.
23. (b) Reuveni, H.; Livnah, N.; Geiger, T.; Klein, S.; Ohne, O.; Cohen, I.; Benhar, M.; Gellerman, G.; Levitski, A. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002, 41, 10304-10314.
24. Donald, A.; McHardy, T.; Rowlands, M. G.; Hunter, L.-J. K.; Davies, T. G.; Berdini, V.; Boyle, R. G.; Aherne, G. W.; Garrett, M. D.; Collins, I. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J. Med. Chem. 2007, 50, 2289-2292.
25. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of novel inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem. 2007, 50, 2293-2296.
26. Caldwell, J. J.; Davies, T. G.; Donald, A.; McHardy, T.; Rowlands, M. G.; Aherne, G. W.; Hunter, L. K.; Taylor, K.; Ruddle, R.; Raynaud, F. I.; Verdonk, M.; Workman, P.; Garret, M.; Collins, I. Identification of 4-(4-Aminopiperidin- l-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. J. Med. Chem. 2008, 51, 2147-2157.
27. Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffman, G. S.; Pandit, J.; Robinson, S.; Wei, L.; Kozina, E.; Marr, E. S.; Borzillo, G.; Knauth, E.; Barbacci-Tobin, E. G.; Vincent, P.; Troutman, M.; Baker, D.; Rajamohan, F.; Kakar, S.; Clark, T.; Morris, J. Synthesis and structure based optimization of novel Akt inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3359-3363.
28. (a) Lin, X.; Murray, J. M.; Rico, A. C.; Wang, M. X.; Chu, D. T.; Zhou, Y.; Del Rosario, M.; Kaufman, S.; Ma, S.; Fang, E.; Crawford, K.; Jefferson, A. B. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg. Med. Chem. Lett. 2006, 16, 4163-4168.
29. (b) Seefeld, M. A.; Rouse, M. B.; McNulty, K. C.; Sun, L.; Wang, J.; Yamashita, D. S.; Luengo, J. I.; Zhang, S.; Minthom, E. A.; Concha, N. O.; Heerding, D. A. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19 (8), 2244-2248.
30. Rouse, M. B.; Seefeld, M. A.; Leber, J. D.; McNulty, K. C.; Sun, L.; Miller, W. H.; Zhang, S.; Minthorn, E. A.; Concha, N. O.; Choudhry, A. E.; Schaber, M. D.; Heerding, D. A. Aminofurazans as potent inhibitors of AKT kinase. Bioorg. Med. Chem. Lett. 2009, 19(5), 1508-1511.
31. Heerding, D. A.; Rhodes, N.; Leber, J. D.; Clark, T. J.; Keenan, R. M.; Lafrance, L. V.; Li, M.; Safonov, I. G.; Takata, D. T.; Venslavsky, J. W.; Yamashita, D. S.; Choudhry, A. E.; Copeland, R. A.; Lai, Z.; Schaber, M. D.; Tummino, P. J.; Strum, S. L.; Wood, E. R.; Duckett, D. R.; Eberwein, D.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Zhang, S.; Minthorn, E. A.; Concha, N. O.; Warren, G. L.; Kumar, R. Identification of 4-(2-(4-amino-l,2,5-oxadiazol-3- yl)-l-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-lH-im idazo[4,5-c]pyridin-4-yl)-2- methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. Med. Chem. 2008, 51, 5663-5679.
32. Coffer, P. J.; Woodgett, J. R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 1991, 201, 475-481.
33. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartmen, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isoenzyme specificity. Bioorg. Med. Chem. Lett. 2005, 15, 761-764.
34. Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Krai, A. M.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R. G.; Huber, H. E. Identification and characterisation of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 2005, 385, 399-408.
35. Tolcher, A. W.; Yap, T. A.; Fearen, I.; Taylor, A.; Carpenter, C.; Brunetto, A. T.; Beeram, M.; Papadopoulos, K.; Yan, L.; de Bono, J. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. 2009, 27 (15s), (Suppl. abstr 3503) (Abstract of presentation at ASCO, American Society of Clinical Oncologists, 2009 Annual Meeting, May 29-Jun 2, Orlando, FL).
36. Davies, T. G.; Verdonk, M. L.; Graham, B.; Saalau-Bethell, S.; Hamlett, C. C.; McHardy, T.; Collins, I.; Garrett, M. D.; Workman, P.; Woodhead, S. J.; Jhoti, H.; Barford, D. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol. 2007, 367, 882-894.
37. Kinase selectivity was determined in the SelectScreen assay, Invitrogen Ltd. Compounds were tested at 1μM, with [ATP] = 10μM, against the following enzymes: CDK2/cyclinA, CHK1, CHK2, CK2αl, EGFR, FGFRl, FLT3, GSK3β, IGFR1, JAK3, KDR, MAPK1, MAPKAPK2, PKA, PKCα, PKCδ, PKCγ, ROCK2, RSK2, p70S6K, SGK1, SRC.
38. Graczyk, P. P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 2007, 50, 5773-5779.
39. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298 (5600), 1912-1916, 1933-1934.
40. Vlietstra, R. J.; van Alewijk, D. C.; Hermans, K. G.; van Steenbrugge, G. J.; Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 58, 2720-2723.
41. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007, 67, 5840-5850.
42. Gowan, S. M.; Hardcastle, A.; Hallsworth, A. E.; Valenti, M. R.; Hunter, L.-J. K.; de Haven Brandon, A. K.; Garrett, M. D.; Raynaud, F.; Workman, P.; Aherne, W.; Eccles, S. A. Application of mesoscale technology for the measurement of phospho-proteins in human tumour xenografts. Assay Drug Dev. Technol. 2007, 5, 391-401.
43. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
44. Moreno-Farre, J.; Workman, P.; Raynaud, F. I. Analysis of potential drug-drug interactions for anticancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay. Recent Adv. Res. Updates 2006, 7, 207-224.
45. (a) Said, S. H.; Karickhoff, S.W.; Carreira, L. A. A rigorous test for SPARC'S chemical reactivity models: estimation of more than 4300 ionization pKa's. Quant. Struct. Act. Rel. 1995, 14, 348-355.
46. (b) Milletti, F.; Storchi, L.; Sfoma, G.; Cruciani, G. New and original pKa prediction method using grid molecular interaction fields. J. Chem. Inf. Model. 2007, 47, 2172-2181.
47. Paliai, P; Goodman, M. Preparation of optically pure monoacyl 2-alkyl gem-diamines from peptide amides. J. Chem. Soc., Chem. Commun. 1982, 280-281.
48. Caldwell, J. J.; Collins, I. Rapid synthesis of 4-benzyl-4-amino- piperidines by addition of Grignard reagents to .N-(l-Boc-piperidin-4-ylidene)- tert-butanesulfinyl imine. Synlett 2006, 2565-2568.
49. Caldwell, J. J.; Cheung, K. M.; Collins, I. Synthesis of 4-(cyclic dialkylamino)-7-azaindoles by microwave heating of 4-halo-7azaindoles and cyclic secondary amines. Tetrahedron Lett. 2007, 48, 1527-1529.
50. (a) Matthews, T. P.; Klair, S.; Burns, S.; Boxall, K.; Cherry, M.; Fisher, M.; Westwood, I. M.; Walton, M. I.; McHardy, T.; Cheung, K.-M. J.; Van Montfort, R.; Williams, D.; Aherne, G. W.; Garrett, M. D.; Reader, J.; Collins, I. Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening. J. Med. Chem. 2009, 52, 4810-4819.
51. (b) Hoehn, H.; Denzel, T. 1H-Pyrazolo[3,4-b]pyridines. Patent Appl. DE2301268. Chem. Abs. 1973, 79, 115578.